 DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical-stage biotechnology company, announced today that it intends to offer and sell its common shares in an underwritten public offering. In addition, DiaMedica intends to grant the underwriters a 30-day option to purchase up to an additional 15 of the common shares offered in the public offering. All of the common shares will be offered by DiaMedica. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 